Authored by Kelly Song via The Epoch Times (emphasis ours) Aduhelm is the brand name under which the Alzheimer’s drug Aducanumab is marketed. It is developed by the U.S. company Biogen. The drug is to be administered as an intra-venous infusion every four weeks. A vial and packaging for the drug Aduhelm is shown on June […]
Source
